Special Issue

Precision Medicine for Neuroblastoma

Message from the Guest Editors

Cancer often is called the poster child of personalized medicine. Thus, it is timely to look at the impact that new molecular insights have had on childhood cancers. This Special Issue of the Journal of Personalized Medicine discusses progress that has been made in neuroblastoma, which is one of the most frequent solid tumours in children and hallmarked by its extreme heterogeneity. Papers in this Special Issue review scientific advances that have improved patient stratification and treatment choices, the introduction of new targeted treatments and immunotherapies in the clinic, new strategies to deal with drug resistance and relapsed disease, and emerging areas, such as the role of tumor metabolism and the tumor microenvironment. Our aim is to provide an overview that includes both scientific and clinical advances on the road to the personalized diagnosis and treatment of neuroblastoma.

Guest Editors

Prof. Dr. Walter Kolch

Systems Biology Ireland, School of Medicine, University College Dublin, Dublin, Ireland

Dr. Cormac Owens

Our Lady's Children's Hospital, Crumlin, Cooley Road, Crumlin Dublin 12, Ireland

Deadline for manuscript submissions

closed (25 September 2021)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/53607

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

